vTv Therapeutics VTVT 深 滬
已收盤 11-06 16:00:00 美东时间
21.03
-0.710
-3.27%
華盛通- 最 高22.5675
- 今 開21.85
- 成交量 1.44万股
- 最 低 20.56
- 昨 收 21.74
- 總市值 8315.30万
- 52周最高 44.00
- 市盈率 靜 --
- 換手率 0.36%
- 52周最低 20.56
- 委 比 -37.46%
- 總股本 395.40万
- 歷史最高 560.00
- 量 比 0.60
- 振 幅 9.23%
- 歷史最低 7.38
- 每 手 1
- 風險率 3.87%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多vTv Therapeutics收跌4.05%，成交额50.43万美元
11月3日，vTv Therapeutics（VTVT）收跌4.05%，报24.15美元，成交额50.43万美元，市值9548.7万美元。 行情数据 • 开盘价...
11-03 08:02
vTv Therapeutics Announces First Patient Randomized In Phase 2a Hybrid CATT1 Study Of Cadisegliatin In Type 1 Diabetes
Phase 2a pilot study aims to inform the design and conduct of future Phase 3 research in this population Cadisegliatin is a potential first-in-class oral therapy being evaluated as an adjunct to insulin for the treatment of T1D HIGH POINT, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics In...
10-27 20:08
vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems
vTv Therapeutics has initiated a Phase 2a pilot study to evaluate cadisegliatin, a potential first-in-class oral therapy, as an adjunct to insulin for individuals with T1D using hybrid closed-loop (HCL) insulin delivery systems. The study aims to inform future research and assess cadisegliatin's impact on glycemic control and hypoglycemia burden. Approximately 40 adults will participate, focusing on CGM-based measures like Time in Range (TIR) and...
10-27 12:00
vTv Therapeutics收涨1.02%，成交额39.41万美元
10月27日，vTv Therapeutics（VTVT）收涨1.02%，报25.81美元，成交额39.41万美元，市值1.02亿美元。 行情数据 • 开盘价...
10-27 07:02
vTv Therapeutics收跌3.81%，成交额31.37万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:05
美股大行评级 | 潜在涨幅325.53%！HC Wainwright维持Alector"买入"评级，目标价上调至8美元
今日重点评级关注：HC Wainwright & Co.：维持Alector"买入"评级，目标价从5美元升至8美元；摩根大通：维持ORIC Pharmaceuticals"超配"评级，目标价从23美元升至26美元
10-15 12:36
BTIG Reiterates Buy on vTv Therapeutics, Maintains $57 Price Target
BTIG analyst Kambiz Yazdi reiterates vTv Therapeutics (NASDAQ:VTVT) with a Buy and maintains $57 price target.
10-14 18:07
国产PDE4B抑制剂III期头对头赢下安进
（来源：求实药社） 10月9日，cAMPfield Therapeutics与恒翼生物（Newsoara Biopharma）公布口服PDE4B选择性抑制剂普瑞...
10-12 11:51
vTv Therapeutics Completes Enrollment In Its Phase 3 Cadisegliatin As Adjunctive Therapy In Type 1 Diabetes Trial
vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that the Company has completed enrollment of its Phase 3 Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes (CATT1...
10-05 20:09
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
vTv Therapeutics granted 2,500 stock options to a non-executive employee under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $31.44 per share, vest over four years, and expire in 10 years. The company is focused on developing cadisegliatin, a potential first-in-class oral adjunctive therapy for type 1 diabetes, currently in a US Phase 3 trial. Cadisegliatin has received Breakthrough Therapy designation from the FDA.
09-15 20:05
